arrow
S

Sue Ann Costa Clemens

University of Siena
H指数:31
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The faces behind vaccination: unpacking the attitudes, knowledge, and practices of staff of Cameroon's Expanded program on Immunization
2023-11-132
OAAI
Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults
2023-07-121
OAAI
The Hidden Impact of the COVID-19 Pandemic on Routine Childhood Immunization Coverage in Cameroon

新型冠状病毒肺炎大流行对喀麦隆常规儿童预防接种覆盖率的隐性影响

2023-03-148
OAAI
Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial
LANCET
IF88.5
2023-01-0119
OAAI
Lessons from the pandemic: Responding to emerging zoonotic viral diseases-a Keystone Symposia report
2022-10-023
OA
Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study

Chadox1-S1新型冠状病毒肺炎疫苗与SCB-2019候选疫苗的同源和异源加强: 一项随机,对照,2期研究

2022-08-1610
OAAI
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
2022-07-019
OAAI
Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR
2022-04-208
OAAI
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study
LANCET
IF88.5
2022-02-01321
OAAI
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial
LANCET
IF88.5
2022-01-0192
OAAI
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

ChAdOx1 nCoV-19 (AZD1222) 疫苗对巴西流行的SARS-CoV-2谱系的功效

2021-10-0638
OAAI